Amicus Therapeutics

Valuation Analysis

About the Company

Amicus Therapeutics en bref

Amicus Therapeutics (FOLD) is currently trading at 12,65 € with a market capitalization of 4,0 Md €. The 52-week range spans from 4,81 € to 12,65 €; the current price is 0.1% below the yearly high. Year-over-year revenue growth stands at +23.7%.

💰 Dividende

Amicus Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

5 analystes évaluent Amicus Therapeutics (FOLD) au consensus : Conserver. L'objectif de cours moyen est de 12,65 €, soit un potentiel de +0.07% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 12,65 € à 12,65 €.

Amicus Therapeutics : la thèse d'investissement en détail

Amicus Therapeutics (FOLD) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 23.7% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 88.5%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

Valorisation en contexte

The EV/EBITDA multiple of 112x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The share is trading at 99.9% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (7.03%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Amicus Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.